At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TNYA Tenaya Therapeutics Inc
Market Closed 10-25 16:00:00 EDT
1.91
+0.08
+4.37%
盘后1.93
+0.02+1.05%
19:54 EDT
High1.99
Low1.84
Vol368.75K
Open1.84
D1 Closing1.83
Amplitude8.20%
Mkt Cap150.68M
Tradable Cap103.53M
Total Shares78.89M
T/O707.78K
T/O Rate0.68%
Tradable Shares54.21M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Optimistic Outlook for Tenaya Therapeutics Amid Positive Trial Developments for TN-201
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301, a small molecule for heart failure with preserved ejection fraction; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.